Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 132

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 132
---
6 to 2007, and from March 2025. Mr. Haviv is a Certified Public Accountant and holds a BA in Accounting
and Economics from Tel-Aviv University, Israel.

Mr. Yaron Eldadhas
served as Chief Financial Officer of Evogene since April 2022. Mr. Eldad has held various chief financial officer positions over the last
25 years in public and private technology and biotechnology companies, including Yamba Group Int. Ltd. from 2011 to 2021, Recoly NV from
2008 to 2010, and e-Sim Ltd. from 1998 to 2007. Mr. Eldad also serves on the board of directors and as chairman of the audit and compensation
committees of B. O. S. Better Online Solutions Ltd. Mr. Eldad holds a B. A. in Economics and Accounting from the Ben-Gurion University of
the Negev, Israel, an Executive MBA in Strategic Management from the Hebrew University of Jerusalem, Israel, and an M. A. in law from the
Bar-Ilan University, Israel.

Dr. Gabi Tarcicwas appointed as Evogene’s Vice President Product in September 2024. Dr. Tarcic has extensive experience in research and development
projects and as a senior executive in the biotech industry. Prior to joining Evogene, from 2012 to 2023, Dr. Tarcic has served in various
positions at Fore Biotherapeutics (formerly NovellusDx Israel), most recently as its Chief Technology Officer. Dr. Tarcic holds a Ph. D.
in life sciences from The Weizmann Institute of Science, Israel.

Dr. Ilia Zhidkovwas appointed as Evogene’s Vice President of Computational Platform in February 2023. Dr. Zhidkov joined Evogene in 2011 as a Bioinformatician
in the Computational Genomics Department and has held various managerial positions in the company over the years. Dr. Zhidkov holds a
Ph. D. in Genetics from Ben Gurion University.

Dr. Elran Haberhas served as Chief Executive Officer of Biomica Ltd., a subsidiary of Evogene, since January 2018. Dr. Haber previously served as Chief
Executive Officer of Therapix Biosciences Ltd. (now known as SciSparc Ltd.) (NASDAQ: SPRC) beginning in November 2015. Prior to that,
from March